Aldeyra therapeutics, inc. (ALDX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Schedule Of Restructuring And Related Costs [Table]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-55,070

-60,826

-58,299

-50,396

-46,120

-38,893

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-22,340

-20,037

-19,829

-18,823

-18,699

-18,403

-16,991

-14,921

-12,090

-10,179

-8,822

-7,725

-5,187

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development

-

6,567

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred taxes

-

-1,309

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

8,150

8,082

7,151

6,272

5,162

4,144

3,719

3,104

2,725

2,714

2,722

2,940

3,008

2,759

2,706

2,366

2,156

2,187

2,105

2,026

2,311

2,037

0

0

0

Non-cash interest expense

388

248

107

82

57

59

16

17

19

20

21

23

25

27

28

31

33

35

40

48

72

150

0

0

0

Accretion on debt securities available for sale, net

475

583

629

586

422

237

119

-6

-59

-129

-248

-282

-271

-266

0

0

0

-

-

-

-

-

-

-

-

Depreciation and amortization expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability, purchase rights and warrant purchase rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Depreciation

-

-

-

-

-

71

56

47

39

37

39

38

37

35

34

31

25

18

0

0

0

-

-

-

-

Change in assets and liabilities:
Prepaid expenses and other current assets

-3,601

454

-937

1,914

3,129

150

560

871

1,406

800

891

261

-22

-278

-357

-6

106

264

404

-2

167

224

0

0

0

Accounts payable

-2,940

-2,846

-3,473

1,292

1,790

2,049

2,957

39

923

725

-248

-60

116

-575

-10

193

171

509

261

250

240

-0

0

0

0

Accrued interest on convertible notes related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Accrued expenses

-1,479

6,041

7,194

-1,176

2,756

3,099

2,238

3,120

295

290

30

-45

487

759

860

647

616

291

252

226

283

776

0

0

0

Net cash used in operating activities

-47,712

-44,984

-41,726

-41,099

-34,534

-29,857

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-14,852

-15,147

-14,243

-13,600

-11,949

-9,311

-7,913

-6,263

-5,555

-4,775

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions of property and equipment

-

9

24

71

128

262

261

213

152

24

11

11

14

11

11

66

93

86

0

0

0

-

-

-

-

Purchases of marketable securities

55,151

57,768

75,018

69,106

64,115

59,731

36,470

37,915

35,952

35,095

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Sales of marketable securities

70,645

75,645

68,200

56,709

44,709

36,659

34,259

32,050

29,817

24,922

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

15,536

18,476

-6,210

-11,907

-18,972

-23,335

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

675

-225

-14,495

-15,116

-13,044

-13,036

0

0

0

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs

10,256

7,891

68,363

69,433

78,551

81,837

14,190

40,008

30,979

37,469

0

0

0

-

-

-

-

-

0

0

0

-

-

-

-

Proceeds from exercise of stock options

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from employee stock purchase plan

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt issuance costs paid in cash

-

123

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

26,421

23,575

81,531

67,800

76,841

80,526

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET DECREASE IN CASH AND CASH EQUIVALENTS

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs not yet paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

333

0

0

0

SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES:
Deferred offering costs paid in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

23,331

12,738

12,688

12,754

19,420

28,469

28,483

28,343

19,146

10,055

0

0

0

NET (DECREASE)/INCREASE IN CASH

-

-

-

-

-

-

-

9,995

1,660

8,008

18,535

-2,997

9,154

-2,633

-16,049

-15,962

-5,572

6,121

20,476

22,033

13,575

5,264

0

0

0

Interest

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

74

74

82

92

96

0

0

0

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Helio Vision, Inc [Member]
Acquired in-process research and development

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired in Helio asset acquisition

-

609

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs of public offerings not yet paid

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Assets acquired

-

75

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Liabilities acquired

-

637

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of securities issued

-

4,944

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets acquired through operating leases

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid during the period for interest

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-